{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:39:52Z","timestamp":1775151592714,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1861,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:p>Raltegravir is a novel HIV\u20101 integrase inhibitor with potent in vitro activity (95% inhibitory concentration = 33 nM in 50% human serum). In vitro characterization of raltegravir inhibition potential was assessed against a panel of cytochrome P450 (CYP) enzymes. An open\u2010label, 2\u2010period study was conducted to assess the effect of raltegravir on the pharmacokinetics of midazolam, a sensitive CYP 3A4 probe substrate: period 1, 2.0 mg of midazolam; period 2, 400 mg of raltegravir every 12 hours for 14 days with 2.0 mg of midazolam on day 14. There was no meaningful in vitro effect of raltegravir on inhibition of a panel of CYP enzymes and induction of CYP 3A4. In the presence of raltegravir, midazolam area under the curve extrapolated to infinity (AUC<jats:sub>0\u2010infin<\/jats:sub>) and maximum plasma concentration (C<jats:sub>max<\/jats:sub>) geometric mean ratios were similar (geometric mean ratios and 90% confidence intervals: 0.92 [0.82, 1.03] (P = .208) and 1.03 [0.87, 1.22] (P = .751), respectively). No substantial differences were observed in T<jats:sub>max<\/jats:sub> (P = .750) or apparent half\u2010life (P = .533) of midazolam. Plasma levels of midazolam were not substantially affected by raltegravir, which implies that raltegravir is not a clinically important inducer or inhibitor of CYP 3A4 and that raltegravir would not be expected to affect the pharmacokinetics of other drugs metabolized by CYP 3A4 to a clinically meaningful extent.<\/jats:p>","DOI":"10.1177\/0091270007310382","type":"journal-article","created":{"date-parts":[[2007,12,13]],"date-time":"2007-12-13T01:54:39Z","timestamp":1197510879000},"page":"209-214","source":"Crossref","is-referenced-by-count":67,"title":["Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro\/In Vivo Correlation"],"prefix":"10.1002","volume":"48","author":[{"given":"Marian","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelem","family":"Kassahun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Troyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisha","family":"Rhoton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia S.","family":"Petry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalyan","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Mangin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel P.","family":"DeNoia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa A.","family":"Wenning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith M.","family":"Gottesdiener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS).2006report on the global AIDS epidemic.http:www.unaids.org. Accessed October 6 2006."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-3527(08)60304-8"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-3527(08)60306-1"},{"key":"e_1_2_5_5_2","unstructured":"MillerMD WitmerM StillmockK et al.Biochemical and antiviral activity of MK\u20100518 a potent HIV integrase inhibitor. Paper presented at: XVI International AIDS Conference;August 1318 2006; Toronto Canada. Abstract THAA0302."},{"key":"e_1_2_5_6_2","unstructured":"SummaV PaceP PetrocchiA et al.Discovery of MK\u20100518 a novel potent and selective HIV integrase inhibitor in phase III clinical trials. Paper presented at: XVI International AIDS Conference;August 1318 2006; Toronto Canada. Abstract THPE0020."},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31802b4956"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60597-2"},{"key":"e_1_2_5_9_2","article-title":"Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects","author":"Iwamoto M","journal-title":"Clin Pharmacol Ther."},{"key":"e_1_2_5_10_2","unstructured":"Panel on Antiretroviral Guidelines for Adult and Adolescents.Guidelines for the use of antiretroviral agents in HIV\u2010infected adults and adolescents. Department of Health and Human Services.October 10 2006.http:www.aidsinfo.nih.govContentFilesAdultandAdolescentsGL.pdf. Accessed October 6 2006."},{"key":"e_1_2_5_11_2","first-page":"88","article-title":"Drug\u2010drug interactions that matter","volume":"14","author":"Back DJ","year":"2006","journal-title":"Top HIV Med."},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103293441307"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.016196"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.11.1352"},{"key":"e_1_2_5_15_2","volume-title":"Drug metabolism\/drug interaction studies in the drug development process: studies in vitro","author":"US Food and Drug Administration","year":"1997"},{"key":"e_1_2_5_16_2","volume-title":"In vivo drug metabolism\/drug interaction studies\u2014study design, data analysis, and recommendations for dosing and labeling","author":"US Food and Drug Administration","year":"1999"},{"key":"e_1_2_5_17_2","volume-title":"Drug interaction studies\u2014study design, data analysis, and implications for dosing and labeling","author":"US Food and Drug Administration","year":"2006"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270007310382","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270007310382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T08:41:25Z","timestamp":1697100085000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270007310382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1177\/0091270007310382"],"URL":"https:\/\/doi.org\/10.1177\/0091270007310382","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}